Katsutoshi Hiramatsu

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review.

Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review.

Journal: Clinical and translational science

Published: October 21, 2023

Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.

Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.

Journal: Drugs - real world outcomes

Published: May 27, 2021

The Prevalence and Diagnostic Ratio of Familial Hypercholesterolemia (FH) and Proportion of Acute Coronary Syndrome in Japanese FH Patients in a Healthcare Record Database Study.

The Prevalence and Diagnostic Ratio of Familial Hypercholesterolemia (FH) and Proportion of Acute Coronary Syndrome in Japanese FH Patients in a Healthcare Record Database Study.

Journal: Cardiovascular therapeutics

Published: December 24, 2019

Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.

Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: September 28, 2018

72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.

72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.

Journal: Advances in therapy

Published: June 21, 2018

Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).

Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).

Journal: Rheumatology and therapy

Published: November 16, 2015

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.

Journal: RMD open

Published: September 25, 2015

Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis.

Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis.

Journal: Clinical and experimental hypertension (New York, N.Y. : 1993)

Published: July 20, 2013

Study of sustained blood pressure-lowering effect of azelnidipine guided by self-measured morning and evening home blood pressure: subgroup analysis of the At-HOME study.

Study of sustained blood pressure-lowering effect of azelnidipine guided by self-measured morning and evening home blood pressure: subgroup analysis of the At-HOME study.

Journal: Drugs in R&D

Published: March 23, 2013

Inhibitory effects of azelnidipine tablets on morning hypertension.

Inhibitory effects of azelnidipine tablets on morning hypertension.

Journal: Drugs in R&D

Published: March 21, 2013

Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study.

Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study.

Journal: Journal of clinical hypertension (Greenwich, Conn.)

Published: March 04, 2013

Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.

Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.

Journal: International heart journal

Published: February 23, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026